D H Whittam1, V Karthikeayan2, E Gibbons2, R Kneen3, S Chandratre4, O Ciccarelli5, Y Hacohen5,6, J de Seze7, K Deiva8, R Q Hintzen9, B Wildemann10, S Jarius10, I Kleiter11,12, K Rostasy13, P Huppke14, B Hemmer15,16, F Paul17, O Aktas18, A K Pröbstel19,20, G Arrambide21, M Tintore21, M P Amato22,23, M Nosadini24, M M Mancardi25, M Capobianco26, Z Illes27, A Siva28, A Altintas29, G Akman-Demir30, L Pandit31, M Apiwattankul32, J Y Hor33, S Viswanathan34, W Qiu35, H J Kim36, I Nakashima37, K Fujihara38,39, S Ramanathan40,41, R C Dale40,41, M Boggild42, S Broadley43, M A Lana-Peixoto44, D K Sato45, S Tenembaum46, P Cabre47, D M Wingerchuk48, B G Weinshenker49, B Greenberg50, M Matiello51, E C Klawiter51, J L Bennett52, A I Wallach53, I Kister53, B L Banwell54, A Traboulsee55, D Pohl56, J Palace4, M I Leite4, M Levy51, R Marignier57, T Solomon2,58, M Lim59,60, S Huda2, A Jacob2,61. 1. Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK. daniel.whittam@nhs.net. 2. Department of Neurology, The Walton Centre NHS Foundation Trust, Liverpool, UK. 3. Department of Paediatric Neurology, Alder Hey Children's Hospital, Liverpool, UK. 4. Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK. 5. Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, UK. 6. Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, UK. 7. Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, Hôpital de Hautepiere, Strasbourg, France. 8. Department of Paediatric Neurology, CHU Paris-Sud, Hôpital de Bicêtre, Le Kremlin Bicêtre, France. 9. Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands. 10. Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. 11. Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany. 12. Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke, Berg, Germany. 13. Department of Paediatric Neurology, Children's Hospital Datteln, Witten/Herdrecke University, Datteln, Germany. 14. Department of Paediatrics and Paediatric Neurology, University Medical Center Göttingen, Georg-August University, Göttingen, Germany. 15. Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany. 16. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 17. NeuroCure Clinical Research Center, and Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany. 18. Department of Neurology, Heinrich-Heine-Universität Düsseldorf, 40225, Düsseldorf, Germany. 19. Department of Neurology and Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. 20. Neurologic Clinic and Policlinic, Department of Medicine and Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland. 21. Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. 22. Department NEUROFARBA, Neurosciences Section, University of Florence, Florence, Italy. 23. IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy. 24. Paediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy. 25. Department of Medical and Surgical Neurosciences and Rehabilitation, IRCCS Giannina Gaslini Institute, Genoa, Italy. 26. Department of Neurology and Regional Multiple Sclerosis Centre, University Hospital San Luigi Gonzaga, Orbassano, Italy. 27. Department of Neurology, Odense University Hospital, Odense, Denmark. 28. Department of Neurology, Istanbul University Cerrahpaşa School of Medicine, Istanbul, Turkey. 29. Department of Neurology, School of Medicine, Koc University, Istanbul, Turkey. 30. Department of Neurology, Bilim University, Istanbul, Turkey. 31. Department of Neurology, Nitte University, Mangalore, Karnataka, India. 32. Neuroimmunology Unit, Department of Neurology, Prasat Neurological Institute, Ministry of Public Health, Bangkok, Thailand. 33. Department of Neurology, Penang General Hospital, Penang, Malaysia. 34. Department of Neurology, Kuala Lumpur Hospital, Ministry of Health of Malaysia, Kuala Lumpur, Malaysia. 35. Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. 36. Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea. 37. Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan. 38. Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine and Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan. 39. MS and NMO Center, Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan. 40. Sydney Medical School, University of Sydney, Sydney, NSW, Australia. 41. Neuroimmunology Group, Kids Neuroscience Centre, Children's Hospital At Westmead, Sydney, NSW, Australia. 42. Department of Neurology, Townsville Hospital, Townsville, QLD, Australia. 43. School of Medicine, Gold Coast Campus, Griffith University, Mount Gravatt, QLD, Australia. 44. CIEM MS Research Center, Federal University of Minas Gerais Medical School, Belo Horizonte, MG, Brazil. 45. Instituto do Cérebro do Rio Grande do Sul (InsCer), Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil. 46. Department of Neurology, National Pediatric Hospital Dr. Juan P. Garrahan, Buenos Aires, Argentina. 47. Department of Neurology, Pierre Zobda Quitman Hospital, Fort-de-France, France. 48. Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA. 49. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 50. Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA. 51. Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 52. Department of Ophthalmology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA. 53. Department of Neurology, NYU School of Medicine, New York, NY, USA. 54. Department of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 55. Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 56. Division of Neurology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada. 57. Service de Neurologie, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Lyon, France. 58. National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK. 59. Children's Neuroscience, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. 60. Faculty of Life Sciences and Medicine, King's College London, London, UK. 61. Department of Neurology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Abstract
INTRODUCTION: While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed. OBJECTIVE: To survey the current global clinical practice of clinicians treating MOGAD. METHOD: Neurologists worldwide with expertise in treating MOGAD participated in an online survey (February-April 2019). RESULTS: Fifty-two responses were received (response rate 60.5%) from 86 invited experts, comprising adult (78.8%, 41/52) and paediatric (21.2%, 11/52) neurologists in 22 countries. All treat acute attacks with high dose corticosteroids. If recovery is incomplete, 71.2% (37/52) proceed next to plasma exchange (PE). 45.5% (5/11) of paediatric neurologists use IV immunoglobulin (IVIg) in preference to PE. Following an acute attack, 55.8% (29/52) of respondents typically continue corticosteroids for ≥ 3 months; though less commonly when treating children. After an index event, 60% (31/51) usually start steroid-sparing maintenance therapy (MT); after ≥ 2 attacks 92.3% (48/52) would start MT. Repeat MOG antibody status is used by 52.9% (27/51) to help decide on MT initiation. Commonly used first line MTs in adults are azathioprine (30.8%, 16/52), mycophenolate mofetil (25.0%, 13/52) and rituximab (17.3%, 9/52). In children, IVIg is the preferred first line MT (54.5%; 6/11). Treatment response is monitored by MRI (53.8%; 28/52), optical coherence tomography (23.1%; 12/52) and MOG antibody titres (36.5%; 19/52). Regardless of monitoring results, 25.0% (13/52) would not stop MT. CONCLUSION: Current treatment of MOGAD is highly variable, indicating a need for consensus-based treatment guidelines, while awaiting definitive clinical trials.
INTRODUCTION: While monophasic and relapsing forms of myelin oligodendrocyte glycoprotein antibody associated disorders (MOGAD) are increasingly diagnosed world-wide, consensus on management is yet to be developed. OBJECTIVE: To survey the current global clinical practice of clinicians treating MOGAD. METHOD: Neurologists worldwide with expertise in treating MOGAD participated in an online survey (February-April 2019). RESULTS: Fifty-two responses were received (response rate 60.5%) from 86 invited experts, comprising adult (78.8%, 41/52) and paediatric (21.2%, 11/52) neurologists in 22 countries. All treat acute attacks with high dose corticosteroids. If recovery is incomplete, 71.2% (37/52) proceed next to plasma exchange (PE). 45.5% (5/11) of paediatric neurologists use IV immunoglobulin (IVIg) in preference to PE. Following an acute attack, 55.8% (29/52) of respondents typically continue corticosteroids for ≥ 3 months; though less commonly when treating children. After an index event, 60% (31/51) usually start steroid-sparing maintenance therapy (MT); after ≥ 2 attacks 92.3% (48/52) would start MT. Repeat MOG antibody status is used by 52.9% (27/51) to help decide on MT initiation. Commonly used first line MTs in adults are azathioprine (30.8%, 16/52), mycophenolate mofetil (25.0%, 13/52) and rituximab (17.3%, 9/52). In children, IVIg is the preferred first line MT (54.5%; 6/11). Treatment response is monitored by MRI (53.8%; 28/52), optical coherence tomography (23.1%; 12/52) and MOG antibody titres (36.5%; 19/52). Regardless of monitoring results, 25.0% (13/52) would not stop MT. CONCLUSION: Current treatment of MOGAD is highly variable, indicating a need for consensus-based treatment guidelines, while awaiting definitive clinical trials.
Authors: Yael Hacohen; Yu Yi Wong; Christian Lechner; Maciej Jurynczyk; Sukhvir Wright; Bahadir Konuskan; Judith Kalser; Anne Lise Poulat; Helene Maurey; Esther Ganelin-Cohen; Evangeline Wassmer; Chery Hemingway; Rob Forsyth; Eva Maria Hennes; M Isabel Leite; Olga Ciccarelli; Banu Anlar; Rogier Hintzen; Romain Marignier; Jacqueline Palace; Matthias Baumann; Kevin Rostásy; Rinze Neuteboom; Kumaran Deiva; Ming Lim Journal: JAMA Neurol Date: 2018-04-01 Impact factor: 18.302
Authors: Brigitte Wildemann; Sven Jarius; Alexander Schwarz; Ricarda Diem; Andrea Viehöver; Stefan Hähnel; Markus Reindl; Mirjam Korporal-Kuhnke Journal: Neurology Date: 2017-06-09 Impact factor: 9.910
Authors: Shahd H M Hamid; Dan Whittam; Mariyam Saviour; Amal Alorainy; Kerry Mutch; Samantha Linaker; Tom Solomon; Maneesh Bhojak; Mark Woodhall; Patrick Waters; Richard Appleton; Martin Duddy; Anu Jacob Journal: JAMA Neurol Date: 2018-01-01 Impact factor: 18.302
Authors: Kevin C O'Connor; Katherine A McLaughlin; Philip L De Jager; Tanuja Chitnis; Estelle Bettelli; Chenqi Xu; William H Robinson; Sunil V Cherry; Amit Bar-Or; Brenda Banwell; Hikoaki Fukaura; Toshiyuki Fukazawa; Silvia Tenembaum; Susan J Wong; Norma P Tavakoli; Zhannat Idrissova; Vissia Viglietta; Kevin Rostasy; Daniela Pohl; Russell C Dale; Mark Freedman; Lawrence Steinman; Guy J Buckle; Vijay K Kuchroo; David A Hafler; Kai W Wucherpfennig Journal: Nat Med Date: 2007-01-12 Impact factor: 53.440
Authors: Giordani Rodrigues Dos Passos; Luana Michelli Oliveira; Bruna Klein da Costa; Samira Luisa Apostolos-Pereira; Dagoberto Callegaro; Kazuo Fujihara; Douglas Kazutoshi Sato Journal: Front Neurol Date: 2018-04-04 Impact factor: 4.003
Authors: S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann Journal: J Neuroinflammation Date: 2018-05-03 Impact factor: 8.322
Authors: Samuel Pearce; Julian T Maingard; Hong Kuan Kok; Christen D Barras; Jeremy H Russell; Joshua A Hirsch; Ronil V Chandra; Ash Jhamb; Vincent Thijs; Mark Brooks; Hamed Asadi Journal: Clin Neuroradiol Date: 2021-03-01 Impact factor: 3.649
Authors: Elia Sechi; Laura Cacciaguerra; John J Chen; Sara Mariotto; Giulia Fadda; Alessandro Dinoto; A Sebastian Lopez-Chiriboga; Sean J Pittock; Eoin P Flanagan Journal: Front Neurol Date: 2022-06-17 Impact factor: 4.086
Authors: Saif Huda; Daniel Whittam; Richard Jackson; Venkatraman Karthikeayan; Patricia Kelly; Sam Linaker; Kerry Mutch; Rachel Kneen; Mark Woodhall; Katy Murray; David Hunt; Patrick Waters; Anu Jacob Journal: BMJ Open Date: 2021-11-30 Impact factor: 2.692